Get the Stockscreener App
0.00
100.00%
-17.16
Ikena Oncology Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$17.16
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$59.90M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
0.00
EPS:
-1.63
Net Cash Flow:
$-80.16M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$23.28
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
0.00 | 59.90M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Energy Moves: How Ikena Oncology Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - BỘ NỘI VỤ
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
How Ikena Oncology Inc. stock performs in interest rate cyclesWeekly Gains Report & Real-Time Market Sentiment Alerts - newser.com
Is Ikena Oncology Inc. stock attractive for ETFsJuly 2025 Breakouts & Weekly High Potential Stock Alerts - newser.com
Will Ikena Oncology Inc. stock sustain high P E ratios2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
How Ikena Oncology Inc. stock trades during market volatilityStock Surge & Scalable Portfolio Growth Ideas - newser.com
What valuation multiples suggest for Ikena Oncology Inc. stockTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
A activity2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Is Ikena Oncology Inc. stock gaining market shareJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Analyzing recovery setups for Ikena Oncology Inc. investorsSell Signal & Reliable Price Action Trade Plans - newser.com
Applying big data sentiment scoring on Ikena Oncology Inc.Quarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Using fundamentals and technicals on Ikena Oncology Inc.Global Markets & High Accuracy Buy Signal Tips - newser.com
Understanding Ikena Oncology Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - newser.com
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
Published on: 2025-11-14 18:20:12 - newser.com
What Fibonacci levels say about Ikena Oncology Inc. rebound2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Is Ikena Oncology Inc. stock a buy on dipsQuarterly Market Summary & AI Enhanced Trading Alerts - Fundação Cultural do Pará
Will Ikena Oncology Inc. stock attract more institutional investors2025 Year in Review & Daily Stock Trend Reports - newser.com
[S-8] ImageneBio, Inc. Employee Benefit Plan Registration | IMA SEC FilingForm S-8 - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results - TradingView
ImageneBio, Inc. SEC 10-Q Report - TradingView
[10-Q] ImageneBio, Inc. Quarterly Earnings Report | IMA SEC FilingForm 10-Q - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - The Manila Times
ImageneBio (Nasdaq: IMA) to amend Phase 2b ADAPTIVE trial; topline data expected 2027 - Stock Titan
How to recover losses in Ikena Oncology Inc. stockTrade Entry Report & Verified Entry Point Signals - newser.com
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):